Ultrasound‐Activated Precise Sono‐Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis
Abstract Immune checkpoint inhibitors have demonstrated remarkable efficacy across various cancer types. However, immune‐related adverse events (irAEs) pose a significant challenge in immunotherapy, particularly the associated pneumonia as the primary adverse reaction, which can lead to irreversible...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202407609 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540908093964288 |
|---|---|
| author | Xiang Li Gao He Hui Jin Xinyu Xiang Dong Li Renmiao Peng Jing Tao Xinping Li Kaiyang Wang Yu Luo Xiaoan Liu |
| author_facet | Xiang Li Gao He Hui Jin Xinyu Xiang Dong Li Renmiao Peng Jing Tao Xinping Li Kaiyang Wang Yu Luo Xiaoan Liu |
| author_sort | Xiang Li |
| collection | DOAJ |
| description | Abstract Immune checkpoint inhibitors have demonstrated remarkable efficacy across various cancer types. However, immune‐related adverse events (irAEs) pose a significant challenge in immunotherapy, particularly the associated pneumonia as the primary adverse reaction, which can lead to irreversible pulmonary fibrosis. Additionally, monotherapy with programmed death ligand (PD‐L1) inhibitors has shown limited effectiveness. Therefore, to improve the response rate of immunotherapy and reduce pulmonary fibrosis, this study designed and prepared an intelligent nanodrug based on dendritic mesoporous silica nanoparticles (DMSNs) loaded with a sono‐sensitive agent protoporphyrin IX (PpIX). Additionally, a reactive oxygen species (ROS) sensitive linker is used to attach the immunotherapeutic drug PD‐L1 inhibitor (aPD‐L1) to DMSNs via covalent bonds. The external ultrasound (US) activates PpIX to generate ROS, which breaks the linker to release aPD‐L1 to induce sonodynamic therapy (SDT) and immunotherapy. This sono‐immnotherapy approach demonstrated excellent outcomes in tumor inhibition, eliciting immune responses, and reducing pulmonary fibrosis. Overall, this study offers a new, efficient, and safe method for breast cancer treatment, and expands the application of immunotherapy. |
| format | Article |
| id | doaj-art-954e8b1f0a2e480195fbde96447a4e8d |
| institution | Kabale University |
| issn | 2198-3844 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj-art-954e8b1f0a2e480195fbde96447a4e8d2025-02-04T13:14:54ZengWileyAdvanced Science2198-38442025-02-01125n/an/a10.1002/advs.202407609Ultrasound‐Activated Precise Sono‐Immunotherapy for Breast Cancer with Reduced Pulmonary FibrosisXiang Li0Gao He1Hui Jin2Xinyu Xiang3Dong Li4Renmiao Peng5Jing Tao6Xinping Li7Kaiyang Wang8Yu Luo9Xiaoan Liu10Department of Thyroid‐Breast Surgery The Fourth Affiliated Hospital of Nanjing Medical University 298 Nanpu Road Nanjing Jiangsu 210032 P. R. ChinaBreast Disease Center The First Affiliated Hospital of Nanjing Medical University 300 Guangzhou Road Nanjing Jiangsu 210029 P. R. ChinaDepartment of Breast surgery The Affiliated Tumor Hospital of Nantong University 30 Tongyang north road Nantong Jiangsu 226361 P. R. ChinaShanghai Engineering Research Center of Pharmaceutical Intelligent Equipment Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non‐coding RNA Institute for Frontier Medical Technology School of Chemistry and Chemical Engineering Shanghai University of Engineering Science Shanghai 201620 P. R. ChinaShanghai Engineering Research Center of Pharmaceutical Intelligent Equipment Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non‐coding RNA Institute for Frontier Medical Technology School of Chemistry and Chemical Engineering Shanghai University of Engineering Science Shanghai 201620 P. R. ChinaShanghai Engineering Research Center of Pharmaceutical Intelligent Equipment Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non‐coding RNA Institute for Frontier Medical Technology School of Chemistry and Chemical Engineering Shanghai University of Engineering Science Shanghai 201620 P. R. ChinaDepartment of Thyroid‐Breast Surgery The Fourth Affiliated Hospital of Nanjing Medical University 298 Nanpu Road Nanjing Jiangsu 210032 P. R. ChinaDepartment of Thyroid‐Breast Surgery The Fourth Affiliated Hospital of Nanjing Medical University 298 Nanpu Road Nanjing Jiangsu 210032 P. R. ChinaShanghai Engineering Research Center of Pharmaceutical Intelligent Equipment Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non‐coding RNA Institute for Frontier Medical Technology School of Chemistry and Chemical Engineering Shanghai University of Engineering Science Shanghai 201620 P. R. ChinaShanghai Engineering Research Center of Pharmaceutical Intelligent Equipment Shanghai Frontiers Science Research Center for Druggability of Cardiovascular Non‐coding RNA Institute for Frontier Medical Technology School of Chemistry and Chemical Engineering Shanghai University of Engineering Science Shanghai 201620 P. R. ChinaBreast Disease Center The First Affiliated Hospital of Nanjing Medical University 300 Guangzhou Road Nanjing Jiangsu 210029 P. R. ChinaAbstract Immune checkpoint inhibitors have demonstrated remarkable efficacy across various cancer types. However, immune‐related adverse events (irAEs) pose a significant challenge in immunotherapy, particularly the associated pneumonia as the primary adverse reaction, which can lead to irreversible pulmonary fibrosis. Additionally, monotherapy with programmed death ligand (PD‐L1) inhibitors has shown limited effectiveness. Therefore, to improve the response rate of immunotherapy and reduce pulmonary fibrosis, this study designed and prepared an intelligent nanodrug based on dendritic mesoporous silica nanoparticles (DMSNs) loaded with a sono‐sensitive agent protoporphyrin IX (PpIX). Additionally, a reactive oxygen species (ROS) sensitive linker is used to attach the immunotherapeutic drug PD‐L1 inhibitor (aPD‐L1) to DMSNs via covalent bonds. The external ultrasound (US) activates PpIX to generate ROS, which breaks the linker to release aPD‐L1 to induce sonodynamic therapy (SDT) and immunotherapy. This sono‐immnotherapy approach demonstrated excellent outcomes in tumor inhibition, eliciting immune responses, and reducing pulmonary fibrosis. Overall, this study offers a new, efficient, and safe method for breast cancer treatment, and expands the application of immunotherapy.https://doi.org/10.1002/advs.202407609breast cancerdendritic mesoporous silicapulmonary fibrosissono‐immunotherapy |
| spellingShingle | Xiang Li Gao He Hui Jin Xinyu Xiang Dong Li Renmiao Peng Jing Tao Xinping Li Kaiyang Wang Yu Luo Xiaoan Liu Ultrasound‐Activated Precise Sono‐Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis Advanced Science breast cancer dendritic mesoporous silica pulmonary fibrosis sono‐immunotherapy |
| title | Ultrasound‐Activated Precise Sono‐Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis |
| title_full | Ultrasound‐Activated Precise Sono‐Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis |
| title_fullStr | Ultrasound‐Activated Precise Sono‐Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis |
| title_full_unstemmed | Ultrasound‐Activated Precise Sono‐Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis |
| title_short | Ultrasound‐Activated Precise Sono‐Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis |
| title_sort | ultrasound activated precise sono immunotherapy for breast cancer with reduced pulmonary fibrosis |
| topic | breast cancer dendritic mesoporous silica pulmonary fibrosis sono‐immunotherapy |
| url | https://doi.org/10.1002/advs.202407609 |
| work_keys_str_mv | AT xiangli ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT gaohe ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT huijin ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT xinyuxiang ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT dongli ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT renmiaopeng ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT jingtao ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT xinpingli ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT kaiyangwang ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT yuluo ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis AT xiaoanliu ultrasoundactivatedprecisesonoimmunotherapyforbreastcancerwithreducedpulmonaryfibrosis |